Anti-Candidal Activity and Functional Mapping of Recombinant and Synthetic Neosartorya fischeri Antifungal Protein 2 (NFAP2) by Tóth, Liliána et al.
ORIGINAL RESEARCH
published: 07 March 2018
doi: 10.3389/fmicb.2018.00393
Frontiers in Microbiology | www.frontiersin.org 1 March 2018 | Volume 9 | Article 393
Edited by:
Hector Mora Montes,
Universidad de Guanajuato, Mexico
Reviewed by:
Ashok K. Chaturvedi,
University of Texas at San Antonio,
United States
Jon Y. Takemoto,
Utah State University, United States
*Correspondence:
László Galgóczy
galgoczi@gmail.com
†These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Fungi and Their Interactions,
a section of the journal
Frontiers in Microbiology
Received: 11 January 2018
Accepted: 21 February 2018
Published: 07 March 2018
Citation:
Tóth L, Váradi G, Borics A, Batta G,
Kele Z, Vendrinszky Á, Tóth R, Ficze H,
Tóth GK, Vágvölgyi C, Marx F and
Galgóczy L (2018) Anti-Candidal
Activity and Functional Mapping of
Recombinant and Synthetic
Neosartorya fischeri Antifungal Protein
2 (NFAP2). Front. Microbiol. 9:393.
doi: 10.3389/fmicb.2018.00393
Anti-Candidal Activity and Functional
Mapping of Recombinant and
Synthetic Neosartorya fischeri
Antifungal Protein 2 (NFAP2)
Liliána Tóth 1,2†, Györgyi Váradi 3†, Attila Borics 4, Gyula Batta 5, Zoltán Kele 3,
Ákos Vendrinszky 3, Roberta Tóth 1, Hargita Ficze 1, Gábor K. Tóth 3,6, Csaba Vágvölgyi 1,
Florentine Marx 7 and László Galgóczy 1*
1Department of Microbiology, Faculty of Science and Informatics, University of Szeged, Szeged, Hungary, 2Doctoral School
in Biology, Faculty of Science and Informatics, University of Szeged, Szeged, Hungary, 3Department of Medical Chemistry,
Faculty of Medicine, University of Szeged, Szeged, Hungary, 4 Institute of Biochemistry, Biological Research Centre,
Hungarian Academy of Sciences, Szeged, Hungary, 5Department of Organic Chemistry, Faculty of Science and Technology,
University of Debrecen, Debrecen, Hungary, 6MTA-SZTE Biomimetic Systems Research Group, University of Szeged,
Szeged, Hungary, 7Division of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
The increasing number of life-threatening Candida infections caused by antifungal
drug-resistant strains urges the development of new therapeutic strategies. The small,
cysteine-rich, and cationic Neosartorya fischeri antifungal protein 2 (NFAP2) effectively
inhibits the growth of Candida spp. Limiting factors of its future application, are the
low-yield production by the native producer, unavailable information about potential
clinical application, and the unsolved relationship between the structure and function.
In the present study we adopted a Penicillium chrysogenum-based expression system
for bulk production of recombinant NFAP2. Furthermore, solid-phase peptide synthesis
and native chemical ligation were applied to produce synthetic NFAP2. The average yield
of recombinant and synthetic NFAP2 was 40- and 16-times higher than in the native
producer, respectively. Both proteins were correctly processed, folded, and proved to
be heat-stable. They showed the same minimal inhibitory concentrations as the native
NFAP2 against clinically relevant Candida spp. Minimal inhibitory concentrations were
higher in RPMI 1640 mimicking the human inner fluid than in a low ionic strength medium.
The recombinant NFAP2 interacted synergistically with fluconazole, the first-line Candida
therapeutic agent and significantly decreased its effective in vitro concentrations in RPMI
1640. Functional mapping with synthetic peptide fragments of NFAP2 revealed that not
the evolutionary conserved antimicrobial γ-core motif, but the mid-N-terminal part of the
protein influences the antifungal activity that does not depend on the primary structure
of this region. Preliminary nucleic magnetic resonance measurements signed that the
produced recombinant NFAP2 is suitable for further structural investigations.
Keywords:Neosartorya fischeri antifungal protein 2, recombinant protein, protein synthesis, anti-candidal activity,
protein structure, functional mapping
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INTRODUCTION
In the last two decades, fungal infections caused by different
Candida spp. (such as candidemia and candidiasis) have become
one of themost frequent healthcare associated infections showing
an increasing trend (Lockhart, 2014). In immunocompetent
individuals, the members of this genus often cause common
but easily-to-treat mucocutaneous candidiasis, but this or an
exogenous Candida infection can become systemic, associated
with highmorbidity andmortality rates in immunocompromised
patients (Deorukhkar, 2016). However, overall resistance to
antifungal agents has remained low within the genus (Lockhart,
2014), a trend in resistance due to misuse of antifungal
drugs, especially to azoles and echinocandins has been recently
reported; and multidrug resistant strains are also occurring
(Bailly et al., 2016; Gonçalves et al., 2016). The antifungal
consumption influences the susceptibility profile of Candida
spp. meaning a selective pressure for the resistant strain (Bailly
et al., 2016). There is therefore a need to reduce the application
of routinely administered antifungal drugs by introducing
novel, alternative agents and therapeutic strategies (e.g., drug
combinatory therapy).
Naturally occurring peptides, proteins and their synthetic
derivatives with antifungal activity have been proposed as
potential sources and templates of novel drugs to treat
mycotic infections, and they also have significant commercial
potential on the global market for antifungals in the next
years (Duncan and O’Neil, 2013). The Neosartorya fischeri
antifungal protein 2 (NFAP2) is a novel member of small,
cysteine-rich, and cationic antifungal proteins from filamentous
ascomycetes (Table 1). Within this protein group, NFAP2 and
its putative homologs form a phylogenetically distinct clade
from the well-characterized Penicillium chrysogenum antifungal
protein (PAF) and Penicillium brevicompactum bubble protein
(BP) homologs. Compared to PAF and BP proteins which are
mainly effective against molds, NFAP2 shows a unique high
anti-yeast activity. Namely, the disulphide-bond stabilized and
heat-resistant NFAP2 effectively inhibits the growth of Candida
albicans and non-albicans Candida species in vitro possibly
due to its prompt membrane disruption ability (Tóth et al.,
2016). These last features render NFAP2 exceptionally suitable
as potential commercial preservative, bio-pesticide, and drug
against yeasts. The yield of NFAP2 in the native producer
N. fischeri (Aspergillus fischerianus) NRRL 181 is quite low
(368 ± 19 µg l−1; Tóth et al., 2016) from economic view and
for further comprehensive and detailed investigations. Therefore,
the bulk production of NFAP2 by a “generally recognized as safe”
(GRAS) microorganism or development of a chemical strategy
for its low-cost synthesis is indispensable.
To meet these requirements, we applied in the present study
a recently described P. chrysogenum-based expression system
(Sonderegger et al., 2016), and a native chemical ligation method
(Váradi et al., 2013) to produce recombinant NFAP2 (rNFAP2)
and synthetic NFAP2 (sNFAP2). Our further aims were to
compare their structure and antifungal activity with those of the
native NFAP2 (nNFAP2) from N. fischeriNRRL 181. The applied
protein synthesis method allowed the functional mapping of
NFAP2 to reveal its putative antifungal active site(s). Finally,
we investigated the potential clinical applicability of NFAP2 by
CLSI-M27A3 susceptibility test method (Clinical and Laboratory
Standards Institute, 2008), and its in vitro combination with
fluconazole (FLC).
MATERIALS AND METHODS
Strains and Media
P. chrysogenum minimal medium (PCMM: 2% sucrose, 0.3%
NaNO3, 0.05% KCl, 0.05% MgSO4 × 7 H2O, 0.005% FeSO4 ×
7 H2O (w/v), 0.25% 1M potassium phosphate buffer pH 5.8,
0.01% trace element solution (v/v); trace element solution: 0.1%
FeSO4 × 7 H2O, 0.9% ZnSO4 × 7 H2O, 0.4% CuSO4 × 5 H2O,
0.01% MnSO4 × H2O, 0.01% H3BO3, 0.01% Na2MoO4 × 2
H2O (w/v)) was used to produce rNFAP2 by P. chrysogenum.
To produce 13C/15N-labeled rNFAP2 the nitrogen and carbon
source in PCMM were replaced by 0.3% (w/v) Na15NO3 and 1%
(w/v) 13C-glucose (Euriso-Top, Saarbrücken, Germany).
The antifungal activity of recombinant and synthetic NFAP2,
and synthetic NFAP2 peptide fragments was investigated
against nine yeast isolates (C. albicans American Type Culture
Collection, Manassas, VA, USA, ATCC 10231; Candida
glabrata Centraalbureau voor Schimmelcultures, Utrecht,
The Netherlands, CBS 138; Candida guilliermondii CBS
566; Candida krusei CBS 573; Candida lusitaniae CBS 6936;
Candida parapsilosis CBS 604; Candida tropicalis CBS 94;
Saccharomyces cerevisiae Szeged Microbiology Collection,
Szeged, Hungary, SZMC 0644; and Schizosaccharomyces pombe
SZMC 0142). Susceptibility tests were performed in low ionic
strength broth medium (LCM: 0.5% glucose, 0.25% yeast
extract, 0.0125% peptone (w/v)) and in RPMI 1640 medium
(Sigma-Aldrich, St Louis, MO, USA) supplemented with
0.03% (w/v) L-glutamine and buffered to pH 7.0 with 0.165M
4-morpholinopropanesulfonic acid (Sigma-Aldrich, St Louis,
MO, USA).
Yeasts were maintained on yeast extract glucose medium
(YEGK: 1% glucose; 1% KH2PO4; 0.5% yeast extract, 2% agar
(w/v)), and P. chrysogenum on PCMM supplemented with 2%
(w/v) agar at 4◦C.
Recombinant NFAP2 Production in
Penicillium chrysogenum-Based
Heterologous Expression System
NFAP2 was produced in P. chrysogenum 1paf under the
regulation of the strong paf -promoter as was described
previously (Sonderegger et al., 2016). To generate the NFAP2-
producing P. chrysogenum strain (P. chrysogenum nfap2), first an
expression vector was constructed as presented in Supplementary
Figure 1. Briefly, the part of the cDNA that codes for the mature
N. fischeri NRRL 181 antifungal protein (NFAP) fused to paf
prepro sequence in the pSK275nfap vector (Sonderegger et al.,
2016) was replaced by the cDNA sequence coding for the mature
NFAP2. The nfap2 cDNA partially overlapping with paf pro
sequence and paf 3′-UTR was amplified (Q5 High Fidelity DNA
Polymerase, New England Biolabs, Ipswich, MA, USA) from a
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TABLE 1 | Amino acid sequence and in silico predicted physical and chemical properties of mature NFAP2 and its peptide fragments.
Protein/peptide Number of
amino acids
Molecular
weight (kDa)
Number
of Cys
Number
of Lys/Arg
Theoretical pI Estimated
charge at pH 7
GRAVY
IATSPYYACNCPNNCKHKKGSGCKYHSGPSDKSKVISGKCEWQGGQLNCIAT
NFAP2 52 5.6 6 7/0/ 9.01 +5.2 −0.731
KYHSGPSDKSKVISGKC(-SH)EWQGGQLNC(-SH)IAT
Fragment 1 (Fr-1) 29 3.1 2 4/0 8.79 +2.1 −0.752
IATSPYYAC(-SH)NC(-SH)PNNC(-SH)KHKKGSGC(-SH)/SHUFFLE VARIANT: IAGAHKC(-SH)KPC(-SH)YGYKTNSC(-SH)C(-SH)NSPN
Fragment 2 (Fr-2, Sh-Fr-2) 23 2.5 4 3/0 8.87 +3.0 −0.704
GKC(-SH)EWQGGQLNC(-SH)IAT
Fragment 3 (Fr-3) 15 1.6 2 1/0 5.99 −0.2 −0.373
NNC(-SH)KHKKGSGC(-SH)/SHUFFLE VARIANT: C(-SH)C(-SH)NKGKNKGSH
Fragment 4 (Fr-4, Sh-Fr-4) 11 1.2 2 3/0 9.39 +3.1 −1.682
KYHSGPSDKSKVIS
Fragment 5 (Fr-5) 14 1.5 0 3/0 9.53 +2.1 −1.157
IATSPYYAC(-SH)NC(-SH)P
Fragment 6 (Fr-6) 12 1.3 2 0/0 5.51 −0.2 +0.192
GRAVY, grand average of hydropathy value; NFAP2, Neosartorya fischeri antifungal protein 2.
synthetic construct inserted in EcoRV restriction site of pUC57
(GenScript USA Inc., Piscataway, NJ, USA) using the primers
NFAP2F (5′- GGC CGC TGAGGCCGG TGT−3′) and NFAP2R
(5′- GGC CAA GCT TCG AGA ATC ACA GG−3′). The 273
bp amplicon contained the BbvCI and HindIII restriction sites
at 5′ and 3′ends. After enzymatic digestion with BbvCI and
HindIII (New England Biolabs, Ipswich, MA, USA), the fragment
was ligated into the respective restriction sites of a pGEM-T
vector (Sonderegger et al., 2016) which already contained the
mature NFAP encoding cDNA fused to paf prepro sequence
flanked with the paf 5′- and 3′-UTR regions. With this step, the
nfap cDNA was replaced to nfap2 cDNA. The paf 5′- and 3′-
UTR flanking construct was amplified (Q5 High Fidelity DNA
Polymerase, New England Biolabs, Ipswich, MA, USA) from this
vector using the primer pair 1stF (5′- GGC CCC ATG GTG
GTA AAC AAG TAG TG−3′) / 1stR (5′- GGT GGC GGC CGC
TCT AGA ACT AG−3′), and after digestion with BspMI, NotI
(New England Biolabs, Ipswich, MA, USA) the resulted 1033 bp
amplicon was inserted into the respectively digested pSK275paf
vector (Sonderegger et al., 2016) resulting in the expression
vector pSK275nfap2. Detailed, graphical information is provided
in the Supplementary Material (Supplementary Figure 1).
P. chrysogenum nfap2 was generated by transformation
of P. chrysogenum 1paf as described (Sonderegger et al.,
2016). The gene integration was confirmed by PCR using the
above-mentioned primer pairs NFAP2F/NFAP2R, 1stF/1stR, and
sequencing of the obtained amplicons.
According to Sonderegger et al. (2016), for recombinant
NFAP2 production 2× 108 conidia of P chrysogenum nfap2 were
cultivated in 200ml PCMM for 96 h at 25◦C with continuous
shaking at 200 rpm. NFAP2 was purified from the cell free
culture supernatant by cation-exchange chromatography on
a Bio-ScaleTM Mini Macro-Prep R© High S column (Bio-Rad
Laboratories, Hercules, CA, USA) using the BioLogic Duo
FlowTM system (Bio-Rad Laboratories, Hercules, CA, USA)
following the protocol described for native NFAP2 (Tóth et al.,
2016). The purity was checked on a 4-12% (w/v) Bis-Tris sodium
dodecyl sulfate-polyacrylamide gel (NuPAGETM NovexTM 4–12%
Bis-Tris Protein Gels, 1.5mm, 10-well; Thermo Fisher Scientific,
Waltham, MA, USA) in 1 × MES buffer (Thermo Fisher
Scientific, Waltham, MA, USA) using Coomassie Brillant Blue R-
250 and silver staining. Protein concentrations were determined
spectrophotometrically (A280) considering the respective molar
extinction coefficient for NFAP2 (ε= 1.842).
Synthesis of NFAP2 and Its Fragments
Fragments of NFAP2 as well as shuﬄe variants of them
were prepared using manual solid-phase peptide synthesis
and either Boc or Fmoc chemistry applying N,N’-
dicyclohexylcarbodiimide/hydroxybenzotriazole coupling.
The thioester part (Fr-2t) was synthesized on a Cys-SH resin
as described before (Váradi et al., 2013). Native chemical
ligation of Fr-2t and Fr-1 was performed in 0.1M ammonium
acetate buffer (pH 7.5) containing 3% (v/v) thiophenol at
6–8mg ml−1 peptide concentration at 25◦C. The reaction was
monitored by analytical reversed-phase high performance liquid
chromatography (RP-HPLC). Ligation reached completion in 3–
4 h in all cases. The precipitate was dissolved by adding 10–15%
(v/v) acetonitrile (ACN) and guanidine hydrochloride (6M final
concentration). The reaction mixture was filtered and purified by
semi-preparative RP-HPLC. Oxidation of thiols of the purified
ligation products was carried out in 0.1M ammonium acetate
buffer (0.2mg ml−1 peptide concentration) having the pH of
7.5 containing 1mM glutathione (GSH) and 1mM glutathione
disulphide (GSSG). After 24 h reaction time the mixture was
injected to semi-preparative RP-HPLC and purified.
Production of nNFAP2
nNFAP2 as control for experiments was prepared from the
supernatant of N. fischeri NRRL 181 (Agricultural Research
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Service Culture Collection, National Center for Agricultural
Utilization Research, Peoria, Illinois USA) as described
previously (Tóth et al., 2016).
In Silico Analyses
Themolecular weight, pI, grand average of hydropathy (GRAVY)
value and total net charge of NFAP2 and its peptide fragments
were calculated and predicted by ExPASy ProtParam tool
(Gasteiger et al., 2005), and Protein Calculator v3.4 server (The
Scripps Research Institute; http://www.scripps.edu/~cdputnam/
protcalc.html), respectively. Shuﬄe variants of Fr-2 and Fr-4 were
generated by the random shuﬄe protein generator of Sequence
Manipulation Suite (Stothard, 2000). Secondary structure of
NFAP2 was predicted by PSIPRED (v3.3) Protein Analysis
Workbench (Buchan et al., 2013).
Peptide and Protein Identification
NFAP2 and its peptide fragments were identified by molar
mass measurement using a Micromass Q-TOF Premier mass
spectrometer (Waters MS Technologies, Manchester, UK)
equipped with a nanoelectrospray ion source.
RP-HPLC Purification and Analysis
The crude peptides were purified by semipreparative RP-HPLC
on a Shimadzu-Knauer apparatus (Kyoto, Japan) using the
following solvent system: (A) 0.1% (v/v) trifluoroacetic acid
(TFA), (B) 80% (v/v) ACN, 0.1% (v/v) TFA. Linear gradient
chosen based on the composition of the peptides was used at the
flow rate of 4ml min−1. Peaks were detected at 220 nm. Purity of
the peptides was checked by analytical RP-HPLC on an Agilent
1200 Series HPLC instrument using the same solvent system as
for purification at 1ml min−1 flow rate.
Electronic Circular Dichroism (ECD)
Spectroscopy
ECD spectroscopic measurements were performed using a Jasco-
J815 spectropolarimeter (JASCO Corporation, Tokyo, Japan), in
the far-UV range (185–260 nm). Protein samples were dissolved
in pure H2O in approximately 0.1mg ml−1 concentration and
measured in a 0.1 cm pathlength quartz cuvette. First, ECD
spectra of samples were recorded at 25◦C with a scan speed of
100 nm s−1. The temperature was then gradually increased up
to 95◦C at a rate of 1◦C min−1 using a Peltier thermoelectronic
controller (TE Technology, Traverse City, MI, USA), while
ellipticity data was recorded as a function of temperature at
228 nm, appointed by spectra measured at 25◦C. The system was
allowed to equilibrate for 1min before measurements were taken
at each temperature point.
The obtained melting curves were fitted with an inverse
sigmoidal function of which inflection point designated the
melting temperature (Tm) of the native protein structure.
ECD spectra were also recorded at 95◦C, the final temperature
of the thermal unfolding experiments, then samples were allowed
to cool and measured again after 5min of equilibration at
25◦C. The reported spectra are accumulations of 10 scans, from
which the similarly recorded, corresponding solvent spectrum
was subtracted. Data are given as molar ellipticities. Accurate
protein sample concentrations for the corrections of ECD spectra
were determined using analytical RP-HPLC.
Nucleic Magnetic Resonance (NMR)
Investigation
NMR spectra were recorded with a Bruker Avance II 500 MHz
spectrometer (Billerica, MA, USA), equipped with a 5-mm
inverse gradient “txi” probe head. The 1H 90 degree pulse was
typically 9–12 us, the 13C 90 degree pulse 15.7 us, and the 15N
90 degree pulse of 37 us. 13C-heteronuclear single quantum
coherence (HSQC) spectrum of the unlabeled sNFAP2 (4.5mg
dissolved in 275 µl acetate buffer, pH 4.5, 298K) was obtained
using the manufacturer’s standard “hsqcetgpsi2” pulse program,
with time domains of 2,024 and 700 points, and number of
scans 64. In case of 13C/15N-labeled rNFAP2 the pulse program
“hsqcctetgpsp” was used for constant time experiment (Vuister
and Bax, 1992). 13C/15N-labeled rNFAP2 (1.1mg) was dissolved
in 275 µl acetate buffer, pH 4.5, 298K for this experiment. Time
domains of 2024 and 400 points were used, and the number of
scans was 8 at each increment. Full NMR signal assignment and
spatial structure determination of NFAP2 is in progress.
Antifungal Susceptibility Tests and
Functional Mapping
Antifungal susceptibility tests were performed with nNFAP2,
rNFAP2, and sNFAP2 and its peptide fragments in LCMmedium
against yeast isolates (105 cells ml−1) according to the broth
microdilution method described by Tóth et al. (2016). Final drug
concentration ranged from 25 to 0.098 µg ml−1 for rNFAP2 and
sNFAP2, and from 100 to 6.25 µg ml−1 for the synthetic peptide
fragments. The rNFAP2 was tested against nine yeast isolates,
while the sNFAP2 and the synthetic peptide fragments against
C. albicans ATCC 10231, C. krusei CBS 573, C. parapsilosis CBS
604, and S. cerevisiae SZMC 0644.
The CLSI-M27A3 broth microdilution method (Clinical and
Laboratory Standards Institute, 2008) was applied to determinate
the minimal inhibitory concentrations (MIC) of FLC (Sigma-
Aldrich, St Louis, MO, USA) and rNFAP2 against the Candida
isolates (103 cells ml−1) under clinically approved test conditions.
For this experiment, the rNFAP2 stock was prepared in bidistilled
water, and FLC in dimethyl sulfoxide (DMSO). The investigated
concentration range was 64–0.0625 µg ml−1 for FCL and
100–0.39µgml−1 for rNFAP2.
Antifungal synergism between rNFAP2 and FLC were
investigated using the checkerboard microdilution method
(Eliopoulos and Moellering, 1996) in RPMI 1640 medium
applying the drug stock preparation method and cultivation
conditions described in CLSI-M27A3 document (Clinical and
Laboratory Standards Institute, 2008). C. albicans, C. parapsilosis,
and C. krusei (103 cells ml−1) were involved in the combination
tests. rNFAP2 in final concentrations ranging from 100 to 6.25
µg ml−1 was mixed with the FLC in final concentrations ranging
from the respective MIC of FLC to its fifth two-fold dilution
step. The fractional inhibitory concentration index (FICI) as a
measure of synergism and antagonism was calculated (Johnson
et al., 2004). Synergism was defined as FICI ≤0.5, indifference
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as 0.5 < FICI ≤ 4 and antagonism was defined when FICI > 4
(Odds, 2003).
LCM plates were incubated at 30◦C, while RPMI 1640 plates
at 35◦C for 48 h without shaking, then the absorbance (OD620)
was measured with a microtiter plate reader (SPECTROstar
Nano, BMG Labtech, Ortenberg, Germany) after resuspension
of the cultures with pipette. The absorbance of the untreated
control cultures was referred to 100% growth in each case. MIC
was defined as the lowest antifungal protein, peptide or drug
concentration at which growth was not detected (growth ≤ 5%)
compared to the untreated control.
All susceptibility tests were repeated at least two times in three
replicates.
Propidium Iodide (PI) Staining
Plasma membrane disrupting activity of NFAP2 and its
peptide fragments was investigated by applying the membrane
impermeant, red-fluorescent nuclear and chromosome stain PI.
Mid-log phase C. albicans ATCC 10231 cells (2× 107 cells ml−1)
were treated with MICs of nNFAP, Fr-2-4, and Sh-Fr-2 and 4
(Table 2) in LCM for 10min at 30◦C with continuous shaking at
200 rpm. After the treatment, cells were washed with LCM, and
then stained with 5 µg ml−1 PI for 10min at room temperature
in the dark, and then they were washed again with LCM and
resuspended in final volume of 100 µl LCM. Cells treated with
70% (v/v) ethanol for 10min at 4◦Cwere used as positive staining
control. Untreated cells were used as negative staining control.
Microscopy
Yeast cells were visualized by light and fluorescence microscopy
(Carl Zeiss Axiolab LR 66238C; Zeiss, Oberkochen, Germany)
and photographed with a microscope camera (Zeiss AxioCam
ERc 5s; Zeiss, Oberkochen, Germany).
Statistical Analysis
Microsoft Excel 2010 software (Microsoft, Edmond, WA, USA)
was used to calculate standard deviations.
RESULTS
Generation of rNFAP2 and sNFAP2
The rNFAP2 was secreted into the supernatant of the
P. chrysogenum nfap2 strain, from where it was purified to
homogeneity. Only one protein band was detected by sodium-
dodecyl-sulfate polyacrylamide gel electrophoresis, which
corresponded to the molecular weight of nNFAP2 (Figure 1).
Electrospray ionization mass spectrometry (ESI-MS) analysis
confirmed that the monoisotopic molecular mass of this
protein (5555.4346 Da) corresponded well to the detected
monoisotopic molecular mass of nNFAP2 (5555.4380 Da) (Tóth
et al., 2016) (Figures 2A,B). This result unambiguously proved
the heterologous production of correctly processed NFAP2
with three intramolecular disulphide bonds between the six
cysteine residues. The final rNFAP2 yield was 15 ± 1.2mg l−1
(n= 2).
For the chemical synthesis of NFAP2, the C-terminal half of
NFAP2 (Fragment 1, Fr-1) was prepared, and in addition to this,
the N-terminal half of the protein was synthesized in thioester
form (Fragment 2t, Fr-2t) to allow native chemical ligation
with Fr-1 (Váradi et al., 2013) (Figure 3A). Cysteine thiols of
the ligation products were oxidized to disulphide bridges with
glutathione redox buffer having the GSH:GSSG ratio of 1:1. ESI-
MS analysis revealed the expected molecular mass for sNFAP2,
having three intramolecular disulphide bonds (5555.4731 Da
in Figure 2C). sNFAP2 showed the same migration profile as
nNFAP2 and rNFAP2 in protein gel (Figure 1). The yield of
reduced NFAP2 in native chemical ligation was 40–42%, and that
of the oxidized protein found to be 23–25%. The overall yield of
sNFAP2 was reduced by four HPLC purification steps to 2–3%.
The average of 5–6mg of pure sNFAP2 could be produced from
altogether 280mg of Fr-1 and Fr-2t.
Structural Analysis of rNFAP2 and sNFAP2
RP-HPLC Analysis
RP-HPLC is an appropriate tool for the investigation of
structural features of proteins related to disulphide bond pattern.
TABLE 2 | Minimal inhibitory concentrations of nNFAP2, rNFAP2, sNFAP2 and its peptide fragments in LCM after incubation for 48 h at 30◦C.
MIC (µg ml−1)
Protein, peptide / Fungus nNFAP2 rNFAP2 sNFAP2 Fr-1 Fr-2 Sh-Fr-2 Fr-3 Fr-4 Sh-Fr-4 Fr-5 Fr-6
Candida albicans ATCC 10231 6.25 6.25 6.25 >100 50 50 >100 50 50 >100 >100
Candida glabrata CBS 138 1.56 1.56 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Candida guilliermondii CBS 566 1.56 1.56 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Candida krusei CBS 573 12.5 12.5 12.5 100 50 50 >100 50 50 >100 >100
Candida lusitaniae CBS 6936 3.125 3.125 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Candida parapsilosis CBS 604 1.56 1.56 1.56 >100 50 50 >100 50 50 >100 >100
Candida tropicalis CBS 94 1.56 1.56 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Saccharomyces cerevisiae SZMC 0644 3.125 3.125 3.125 100 50 50 >100 50 50 >100 >100
Schizosaccharomyces pombe SZMC 0142 1.56 1.56 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Fr-1 — Fr-6, synthetic peptide fragments 1-6 of Neosartorya fischeri antifungal protein 2 (Table 1 and Figure 3), MIC, minimal inhibitory concentration, n.d., not determined, nNFAP2,
native NFAP2 produced by N. fischeri NRRL 181, rNFAP2, recombinant NFAP2 produced by P. chrysogenum nfap2, Sh-Fr-2 and Sh-Fr-4, shuffle variant of Fr-2 and Fr-4s, NFAP2,
synthetic NFAP2.
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FIGURE 1 | Appearance of nNFAP2, rNFAP2, and sNFAP2 in 4-12% (w/v)
Bis-Tris sodium dodecyl sulfate-polyacrylamide gel (NuPAGETM NovexTM
4–12% Bis-Tris Protein Gels, 1.5mm, 10-well; Thermo Fisher Scientific,
Waltham, MA, USA) in 1×NuPAGETM MES running buffer (Thermo Fisher
Scientific, Waltham, MA, USA). Protein bands are visualized applying silver
staining. Lane 1: nNFAP2 (2 µg), lane 2: rNFAP2 (10 µg), lane 3: sNFAP2 (10
µg), lane 4: SeeBlueTM Plus2 Pre-stained Protein Standard (Thermo Fisher
Scientific, Waltham, MA, USA). nNFAP2: native NFAP2 produced by N. fischeri
NRRL 181, rNFAP2: recombinant NFAP2 produced by P. chrysogenum nfap2,
sNFAP2: synthetic NFAP2.
Formation of interlocking disulphide bridges characteristic
for small, cysteine-rich antifungal proteins from filamentous
ascomycetes results in decreased retention time on a reversed-
phase column. RP-HPLC revealed the same retention time for
the rNFAP2 and sNFAP2 as for the native one confirming right
pairing of cysteines and native fold of the recombinant and
synthetic proteins (Figure 4). The RP-HPLC purified protein
samples were used in the further structural investigation
experiments.
ECD Spectroscopy
ECD spectra of all NFAP2 samples (Figure 5A) show features
highly similar to those reported earlier for this class of
proteins (Fizil et al., 2015; Sonderegger et al., 2016; Tóth
et al., 2016; Galgóczy et al., 2017; Garrigues et al., 2017), with
contributions emerging from β-conformation (200 nm, 212 nm)
and disulphide bridges (228 nm). In fact, all NFAP2 samples
possessed identical secondary structural elements regardless
of their native, recombinant or synthetic origin (Figure 5A).
Thermal unfolding experiments followed by ECD indicated,
that the native folds of nNFAP2, rNFAP2, and sNFAP2 remain
intact up to approximately 70◦C (Figure 5B), and thermal
denaturation is reversible (Supplementary Figure 2). This
contradicts previous observations taken for nNFAP2 samples
purified by dialysis, where only partial structural reorganization
was observed, even 4 weeks after the annealing (Tóth et al.,
2016). This discrepancy may be attributed to higher integrity of
samples purified by RP-HPLC as opposed to those purified by
dialysis.
NMR Measurements
NMR investigations requiremilligrams of isotope-labeled protein
to reveal the tertiary structure and structural dynamics. Hence,
the production of isotope-labeled NFAP2 by the native producer
N. fischeri NRRL 181 is not economic because of the low protein
yield and expense of isotope labeled compounds. Considering the
data collected with ESI-MS, RP-HPLC, and ECD that revealed
very similar structures of sNFAP2, rNFAP2 and nNFAP2, we
started the preliminary NMR investigations with unlabeled
sNFAP2 and 13C/15N-labeled rNFAP2. First, we confirmed the
structure identity of sNFAP2 and rNFAP2 using the 13C-
HSQC type fingerprint spectra of the two compounds. The
methyl region of sNFAP2 (blue in Figure 6A) and rNFAP2
(red, intentionally shifted up in Figure 6A) are expanded and
overlaid, while Figure 6B shows a bigger range of the aliphatic
CH region. Though the signal intensities are different due to
different relaxation behavior and the constant-time version of
HSQC experiment necessary to remove 13C-13C couplings in
the rNFAP2, it can be seen that nearly all HSQC peak has a
pair, a closest neighbor in the map. This observation strongly
suggests, that the two compounds have identical constitution
and even more very similar, folded spatial structure. Considering
these results, the 13C/15N-labeled rNFAP2 is a suitable object to
reveal the folded structure and structural dynamics of NFAP2.
The NMR assignment and 3D structure determination of NFAP2
is in progress.
Antifungal Activity of rNFAP2 and sNFAP2
Antifungal Activity in LCM
nNFAP2, rNFAP2, and sNFAP2 totally inhibited the yeast growth
after 48 h at their applied concentration range, and there was
no difference between their MICs (Table 2). The MICs varied in
the range of 1.56–12.5 µg ml−1 depending on the tested species.
Both, the rNFAP2 and the sNFAP2 showed dose-dependent
antifungal activity (Supplementary Figures 3A,B). However,
sNFAP2 was tested against only four species because of its low-
yield production, but based on the results of the susceptibility
tests (Table 2) we expect the sameMICs to nNFAP2 and rNFAP2
against the other non-investigated isolates. Our results propose
the potential clinical applicability of the high-yield produced
rNFAP2.
Antifungal Activity in RPMI 1640
To determine MICs of rNFAP2 under standardized clinical
microbiological conditions, its in vitro antifungal activity was
investigated against human pathogenic Candida spp. in human
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FIGURE 2 | Monoisotopic molecular mass (+H+) of (A) nNFAP2, (B) rNFAP2 and (C) sNFAP2. nNFAP2: native NFAP2 produced by N. fischeri NRRL 181, rNFAP2:
recombinant NFAP2 produced by P. chrysogenum nfap2, sNFAP2: synthetic NFAP2.
FIGURE 3 | Synthesis strategy of NFAP2 and its peptide fragments. (A) Two synthetic peptides, Fragment 2t (thioester form), and Fragment 1, were linked by native
chemical ligation (Váradi et al., 2013) to produce full-length synthetic NFAP2. (B) The synthetized peptide fragments for functional mapping cover the full-length
protein. Intramolecular disulphide bridges between cysteines are marked with orange lines and the γ-core motif in red letters.
inner fluid mimicking RPMI 1640 medium following the
recommendations of CLSI-M27A3 susceptibility test method
(Clinical and Laboratory Standards Institute, 2008). MICs are
summarized in Table 3. C. albicans, C. krusei, C. lusitaniae, and
C. tropicalis showed higher MICs than 100 µgml−1, however
this applied concentration could reduce the fungal growth to
30 and 50% except of C. krusei (Supplementary Figure 4). The
growth of C. glabrata, C. guilliermondii, and C. parapsilosis was
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FIGURE 4 | RP-HPLC chromatogram of (A) rNFAP2, (B) sNFAP2, and
(C) nNFAP2. A linear gradient was applied from 5 to 35% (v/v) solvent (B) in
30min. nNFAP2: native NFAP2 produced by N. fischeri NRRL 181, rNFAP2:
recombinant NFAP2 produced by P. chrysogenum nfap2, sNFAP2: synthetic
NFAP2.
completely inhibited in the investigated concentration range with
MICs of 12.5, 3.125, and 100 µgml−1, respectively (Table 3).
These results sign the limited clinical applicability of NFAP2 as
FIGURE 5 | (A) ECD spectra of nNFAP2 (blue), rNFAP2 (red), and sNFAP2
(green), recorded at 25◦C. (B) Thermal unfolding curves measured at 228 nm
for nNFAP2 (blue, Tm = 72.92
◦C, R2 = 0.9837), rNFAP2 (red, Tm = 75.79◦C,
R2 = 0.9942), and sNFAP2 (green, Tm = 74.94◦C, R2 = 0.9864). nNFAP2:
native NFAP2 produced by N. fischeri NRRL 181, rNFAP2: recombinant
NFAP2 produced by P. chrysogenum nfap2, sNFAP2: synthetic NFAP2.
monotherapeutic and systemic antifungal drug. Thus, its efficacy
in combinatorial drug application was investigated.
Combination of rNFAP2 With FLC
C. albicans andC. parapsilosis as themost prevalent opportunistic
pathogen of adults and neonates, and C. krusei as the most
frequent azole-resistant species (Guinea, 2014) were involved in
the combination tests under the same conditions described in
the CLSI-M27A3 method (Clinical and Laboratory Standards
Institute, 2008). The combination of rNFAP2 with FLC, the
first-line therapeutic drug in treatment of Candida infections
(Lockhart, 2014) was studied. To calculate the fractional
inhibitory concentration index (FICI) to reveal the synergism
between the compounds, exact MICs of rNFAP2 and FLC
were determined (Table 3). Co-administration of rNFAP2 and
FLC acted synergistically (FICI = 0.28 and 0.19) against
C. albicans and C. parapsilosis (Table 3), while it was indifferent
(FICI = 0.52) at C. krusei (Table 3). The effective combinations
of rNFAP2 and FLC are shown in Supplementary Figure 5.
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FIGURE 6 | 13C-1H HSQC spectra of rNFAP2 and sNFAP2: (A) Methyl and
(B) aliphatic CH region of rNFAP2 (red) and sNFAP2 (blue). Overlaid spectra
are intentionally shifted in the vertical 13C axis direction for better visibility.
rNFAP2: recombinant NFAP2 produced by P. chrysogenum nfap2, sNFAP2:
synthetic NFAP2.
Functional Mapping of NFAP2
Peptide motifs derived from a full-length antifungal protein
allow the identification of putative antimicrobial active motifs
(Garrigues et al., 2017). Considering this approach, we involved
six synthetic peptide fragments (Fr 1-6) of NFAP2 (Fragments
1–6 in Table 1 and Figure 3B) in antifungal activity assays to
identify the functional active site(s) of the protein. Solid-phase
peptide synthesis was applied to prepare peptide fragments of
NFAP2. Two halves (Fr-1 and Fr-2 in Table 1) and four quarters
(Fr-3-6 in Table 1) were synthesized on a solid support applying
either Boc or Fmoc chemistry (Figure 3B). Besides this, shuﬄe
variants of Fr-2 and Fr-4 (Sh-Fr-2 and Sh-Fr-4 in Table 1) were
prepared using the same method. Peptides were purified by
preparative RP-HPLC. Analytical RP-HPLC showed high purity
of the products, and ESI-MS confirmed the expected molecular
mass of them (data not shown).
In LCM, only Fr-2 and Fr-4 showed dose-dependent
antifungal activity (Supplementary Figures 6A,C), and their
MICs were much higher than the full-length NFAP2 (Table 2).
At their MICs they exerted the prompt plasma membrane
disruption effect on C. albicans (Figure 7) what we already
observed at nNFAP2 by applying PI staining (Tóth et al., 2016).
Taking into account that the Fr-4 is the C-terminal part of the Fr-
2, and the N-terminal Fr-6 part of Fr-2 did not show antifungal
activity (Figure 3B and Table 2), we assume that the mid-N-
terminal part of the protein (Fr-4 in Figure 3B) influences the
antifungal activity.
Previous studies demonstrated that synthetic peptide
fragments of antifungal proteins and their rational-designed
variants show remarkable inhibitory potential on fungi if they
are hydrophilic and have high positive net-charge (Sagaram
et al., 2011; Garrigues et al., 2017). Therefore, we were curious
whether the observed antifungal activity of Fr-2 and Fr-4
depends on these features or the primary structure. Hence, we
also involved the shuﬄe variants of these two peptides (Sh-Fr-2
and Sh-Fr-4 in Table 1) in antifungal activity assays. Both shuﬄe
variants showed the same inhibitory potential as Fr-2 and Fr-4
(Supplementary Figures 6B,D, Table 2) and the prompt plasma
membrane disruption effect (Figure 7). We conclude that the
antifungal activity of NFAP2 does not depend on the primary
structure of the mid-N-terminal region, but possibly on the net
charge and hydrophilicity.
The C-terminal part of NFAP2 contains the consensus γ-
core motif [GXC]-[X3−9]-[C] (Figure 3A), which is important
for the activity or folding of antifungal proteins from animals,
humans, and antifungal plant defensins (Lacerda et al., 2014).
Interestingly, the peptide fragment containing the γ-core motif
of NFAP2 (N-GKCEWQGGQLNC-C) (Fr-3 in Figure 3B) was
inactive against yeasts (Table 2) and did not disrupt the plasma
membrane (Figure 7) indicating that this specific motif alone
has no anti-yeast function, but presumably needs the structural-
functional support from other parts of NFAP2. The experimental
proof of this hypothesis is in progress.
DISCUSSION
In the present study, we generated functional recombinant
and synthetic NFAP2 which underlines the applicability
of heterologous expression and chemical synthesis in the
production of cysteine-rich antifungal proteins. Recombinant
production of the NFAP by the P. chrysogenum-based expression
system has been reported recently, however the NFAP
yield reached only three-times that of the native producer
(Sonderegger et al., 2016). In the present study, the average yield
of rNFAP2 was approx. 40-times higher than in N. fischeri NRRL
181 (Tóth et al., 2016). It is worth to mention that the applied
P. chrysogenum Q176 strain is recognized as GRAS organism
by the US Food and Drug Administration. However, chemical
synthesis of ascomycetous cysteine-rich antifungal proteins has
been described previously: functional PAF was produced by
solid-phase peptide synthesis and native chemical ligation by
Váradi et al. (2013). Here, we show out that this synthesis method
is also suitable to generate other functional and phylogenetically
distinct cysteine-rich antifungal protein from PAF, the NFAP2.
The correct folding is mandatory for full antifungal activity.
This correlation was proved for NFAP (Galgóczy et al., 2017). The
data collected with ESI-MS, RP-HPLC, ECD and NMR verified
the correct processing and folding of rNFAP2 and sNFAP2.
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TABLE 3 | Minimal inhibitory concentrations of rNFAP2 and FLC, and their combination in RPMI 1640 after incubation for 48 h at 35◦C.
Protein, peptide / Species MIC (µg ml−1) FICI Effect in combination
rNFAP2(a) FLC(a) rNFAP2(c) FLC(c)
Candida albicans ATCC 10231 200* 1 6.25 0.25 0.28 synergistic
Candida glabrata CBS 138 12.5 n.d. n.d. n.d. n.d. n.d.
Candida guilliermondii CBS 566 3.125 n.d. n.d. n.d. n.d. n.d.
Candida krusei CBS 573 400* 64 6.25 64 0.52 indifferent
Candida lusitaniae CBS 6936 >100 n.d. n.d. n.d. n.d. n.d.
Candida parapsilosis CBS 604 100 8 6.25 1 0.19 synergistic
Candida tropicalis CBS 94 >100 n.d. n.d. n.d. n.d. n.d.
*The individual MIC above 100 µgml−1 was determined to calculate FICI for the respective strains. (a): MIC of the drug alone, (c): MIC of the drug in combination. FICI: fractional
inhibitory concentration index, FLC: fluconazole, MIC: minimal inhibitory concentration, n.d.: not determined, rNFAP2: recombinant NFAP2 produced by P. chrysogenum nfap2.
FIGURE 7 | PI staining of C. albicans ATCC 10231 cells after treatment at MIC (Table 2) of nNFAP2 and its synthetic peptide fragments (Fr-2 - 4 and Sh-Fr-2 and 4) for
10min at 30◦C. Scale bars represent 20µm. 70% (v/v) Et-OH: positive PI-staining control, C: untreated, negative control, Fr-2 - 4: synthetic peptide Fragment 2 - 4 of
NFAP2 (Table 1), nNFAP2: native NFAP2 produced by N. fischeri NRRL 181, Sh-Fr-2 and 4: shuffle variants of synthetic peptide Fragment 2 and 4 of NFAP2 (Table 1).
Considering the structural identity between the rNFAP2 and
nNFAP2, the 13C/15N-labeled rNFAP2 is a suitable object to
analyse the tertiary structure and folding dynamics of NFAP2,
which is currently in progress.
The antifungal activity of recombinant and synthetic NFAP2
was the same to the native protein and they exerted fungicidal
activity on yeasts after 2 days of exposure. This observation
and the easy production of high-yield rNFAP2 could open new
perspectives for its medical application as a novel antifungal
agent to treat problematic Candida infections caused by strains
resistant to clinically administrated antifungal drugs. However,
rNFAP2 showed remarkable antifungal effect in LCM, its activity
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dramatically decreased in the complex RPMI 1640 medium
(Tables 2, 3). As RPMI 1640 mimics the composition of
human fluids, systemic application of NFAP2 as monotherapy
is questionable, but the topical application might be successful
as suggested for PAF (Galgóczy et al., 2008). In agreement
with our observation, high MICs in RPMI 1640 medium for
PAF and NFAP have been reported against human pathogenic
dermatophytes (Galgóczy et al., 2008), aspergilli and fusaria
(Virágh et al, 2014). The reason for this phenomenon could be
the high cation concentration of this medium which reduces the
antifungal efficacy of PAF (Kaiserer et al., 2003; Sonderegger et al.,
2017) and NFAP (Galgóczy et al., 2017).
Combinatorial application of antifungal agents with different
mode of action and metabolism is taken into consideration
when the infective fungus shows low susceptibility or resistance
to one of them, and/or prolonged sole drug administration
in high-dosage can cause severe side-effects in the host. Co-
administration strategy allows reduction in drug dosage, can
shorten the period of effective treatment and decrease the risk
of side-effects. FLC is inexpensive, readily available and the
most frequently prescribed antifungal agent worldwide to treat
Candida infections. However, an emergence in the number of
less susceptible or resistant Candida strains has been recently
reported (Bailly et al., 2016; Gonçalves et al., 2016). The
combination of NFAP2 with FLC reduced its effective in vitro
dosage in a synergistic or additive way, as demonstrated for
PAF in a previous study (Galgóczy et al., 2008). Based on these
promising results, the FLC-antifungal protein combination could
represent a novel therapeutic strategy in the treatment of fungal
infections. Detailed in vivo pharmacotherapy and clinical studies
are required to prove this assumption.
Functional mapping of a protein provides a platform to
identify functionally active sites of the molecule which is
indispensable for its rational design to develop novel antifungal
molecules with improved activity, efficacy and selectivity. In
antifungal plant defensins the presence of the consensus [GXC]-
[X3−9]-[C] γ-core motif determines the antimicrobial activity
(Lacerda et al., 2014). A high number of hydrophilic, positively
charged amino acids in the γ-core motif of defensins promote
cell-killing, while more hydrophobic and negatively charged
amino acids trigger morphogenic effect on hyphae. Interestingly,
synthetic plant defensin peptides that span the γ-core show the
same antimicrobial effect as the full-length proteins (Sagaram
et al., 2011). Membrane disruption activity of hydrophilic
and cationic antimicrobial peptides on Candida spp. has been
already proved (Nawrot et al., 2013; Swidergall and Ernst, 2014).
Functional mapping of NFAP2 identified the functionally active
motif C-NNCKHKKGSGC-N to reside in the mid-N-terminal
part of the protein, not to γ-core motif C-GKCEWQGGQLNC-
N that localizes in the C-terminus. This C-terminal part of
the protein is almost neutrally charged (estimated net charge
at pH = 7.0 is −0.2) and slightly hydrophilic (GRAVY value
is −0.993) in contrast to the mid-N-terminal part which
contains several positively charged (estimated net charge at
pH = 7.0 is +3.1) and hydrophilic amino acids (GRAVY value
is −1.682). In silico structural prediction indicated that this
part of the protein forms a surface accessible, elongated and
flexible loop region that protrudes from a compact tertiary
structure (Supplementary Figure 7). This and the PI-staining
results (Figure 7) let us purpose that the C-NNCKHKKGSGC-
N region determines the membrane disruption ability of NFAP2
(Tóth et al., 2016). The shuﬄe variant of this protein region also
disrupted the C. albians cell membrane within short exposure
time (Figure 7) indicating that the high positive charge and
hydrophilicity could be the key to the cell-killing effect, not
the primary structure. It is worth to mention that ECD spectra
of synthetic NFAP2 fragments indicated the absence of stable
secondary structural elements both for the antifungal inactive
and active ones (Supplementary Figure 8).
In conclusion, our study significantly contributes to a better
understanding of the structure-function relationship of NFAP2
and related proteins, which is a prerequisite for their possible
application as antifungal agents or the development of new
antifungal strategies against Candida infections in the future.
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